PURPOSE: The body distribution of total radioactivity (TR) and bortezomib was investigated in male Sprague-Dawley rats after single and repeated i.v. (bolus) administration with (14)C-labelled bortezomib (VELCADE) (0.2 mg/kg; 0.28 MBq./kg). METHODS: Bortezomib was dosed on days 1, 4, 8, and 11 (i.e. a clinical dosing cycle) and the animals were sacrificed at selected time points following single and repeated dose administration for the quantification of TR in blood, plasma, and various tissues by liquid scintillation counting following organ dissection or by quantitative whole body autoradiography. In selected tissues, bortezomib levels were determined by LC-MS/MS. RESULTS: In general, plasma TR levels were less than 10% of the corresponding blood concentrations. TR was rapidly and widely distributed to the tissues with only limited penetration into the central nervous system (CNS). In the tissues, highest levels of TR were measured in bortezomib-eliminating organs (liver and kidney), lymphoid tissues, and regions of rapidly dividing cells (e.g. the bone marrow, intestinal mucosa). Low TR concentrations were found in the CNS (tissue-to-blood ratio of approximately 0.05 after repeated dosing). With the exception of the liver, TR consisted almost exclusively of the parent drug. Tissue concentrations of TR and bortezomib increased up to about threefold from the first to the third dose administration, after which they remained constant. CONCLUSION: No undue tissue accumulation of TR and of bortezomib was observed in rats following a full clinical dosing cycle of bortezomib.
PURPOSE: The body distribution of total radioactivity (TR) and bortezomib was investigated in male Sprague-Dawley rats after single and repeated i.v. (bolus) administration with (14)C-labelled bortezomib (VELCADE) (0.2 mg/kg; 0.28 MBq./kg). METHODS:Bortezomib was dosed on days 1, 4, 8, and 11 (i.e. a clinical dosing cycle) and the animals were sacrificed at selected time points following single and repeated dose administration for the quantification of TR in blood, plasma, and various tissues by liquid scintillation counting following organ dissection or by quantitative whole body autoradiography. In selected tissues, bortezomib levels were determined by LC-MS/MS. RESULTS: In general, plasma TR levels were less than 10% of the corresponding blood concentrations. TR was rapidly and widely distributed to the tissues with only limited penetration into the central nervous system (CNS). In the tissues, highest levels of TR were measured in bortezomib-eliminating organs (liver and kidney), lymphoid tissues, and regions of rapidly dividing cells (e.g. the bone marrow, intestinal mucosa). Low TR concentrations were found in the CNS (tissue-to-blood ratio of approximately 0.05 after repeated dosing). With the exception of the liver, TR consisted almost exclusively of the parent drug. Tissue concentrations of TR and bortezomib increased up to about threefold from the first to the third dose administration, after which they remained constant. CONCLUSION: No undue tissue accumulation of TR and of bortezomib was observed in rats following a full clinical dosing cycle of bortezomib.
Authors: Toyoko Hiroi; Clayton B Deming; Haige Zhao; Baranda S Hansen; Elisabeth K Arkenbout; Thomas J Myers; Michael A McDevitt; Jeffrey J Rade Journal: Arterioscler Thromb Vasc Biol Date: 2009-08-06 Impact factor: 8.311
Authors: Dominika Nowis; Michał Maczewski; Urszula Mackiewicz; Marek Kujawa; Anna Ratajska; Mariusz R Wieckowski; Grzegorz M Wilczyński; Monika Malinowska; Jacek Bil; Pawel Salwa; Marek Bugajski; Cezary Wójcik; Maciej Siński; Piotr Abramczyk; Magdalena Winiarska; Anna Dabrowska-Iwanicka; Jerzy Duszyński; Marek Jakóbisiak; Jakub Golab Journal: Am J Pathol Date: 2010-06 Impact factor: 4.307
Authors: Bret B Friday; S Keith Anderson; Jan Buckner; Chunrong Yu; Caterina Giannini; Francois Geoffroy; John Schwerkoske; Miroslaw Mazurczak; Howard Gross; Eduardo Pajon; Kurt Jaeckle; Evanthia Galanis Journal: Neuro Oncol Date: 2011-11-16 Impact factor: 12.300
Authors: Daniela A Bota; Daniela Alexandru; Stephen T Keir; Darell Bigner; James Vredenburgh; Henry S Friedman Journal: J Neurosurg Date: 2013-10-04 Impact factor: 5.115
Authors: Deborah J Kuhn; Sally A Hunsucker; Qing Chen; Peter M Voorhees; Marian Orlowski; Robert Z Orlowski Journal: Blood Date: 2008-12-02 Impact factor: 22.113
Authors: Eri Taniguchi; Min Jung Cho; Benjamin R Arenkiel; Mark S Hansen; Omar J Rivera; Amanda T McCleish; Stephen J Qualman; Denis C Guttridge; Matthew P Scott; Mario R Capecchi; Charles Keller Journal: Pediatr Blood Cancer Date: 2009-08 Impact factor: 3.167